ScreenPoint Transpara vs Viz.ai

Transpara has eight FDA 510(k)s, the newest K260898 from August 2026, and ScreenPoint says it was the AI in the MASAI trial, which Lund University ran and the Lancet journals published. The vendor reports sensitivity of 80.5% against 73.8% for standard double reading, at 98.5% specificity over 105,000 women. A breast screening program reading 2D and 3D mammograms is who it serves. Viz.ai answers a different call, a large vessel occlusion alert pushed to the on-call team's mobile app, and a stroke network that transfers patients between hospitals is the customer. A screening program and a stroke network never end up on the same shortlist, so neither tool takes a buyer from the other. ContaCT, the LVO software, was authorized through a De Novo on February 13, 2018 as radiological computer-assisted triage and notification on CTA. A meta-analysis of 12 studies and 15,595 patients found shorter door-to-groin and door-in-door-out times and no significant difference in clinical outcomes. Viz.ai says it is embedded in 2,000 hospitals.